Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization (ABPARO-Studie)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00707369
Recruitment Status : Completed
First Posted : June 30, 2008
Last Update Posted : March 3, 2015
Sponsor:
Information provided by (Responsible Party):
Benjamin Ehmke, University Hospital Muenster

Brief Summary:
The purpose of this study is to determine the size of the benefit of an adjunctive empiric antibiotic therapy compared to standard mechanical debridement and oral hygiene instructions in a representative sample of German periodontitis patients.

Condition or disease Intervention/treatment Phase
Periodontitis Drug: Amoxicillin and Metronidazole Drug: Placebo Phase 4

Detailed Description:

Periodontitis is an endemic inflammatory disease caused by a mixed bacterial biofilm infection that is followed by destruction of tooth supporting tissues. Standard of care consists of lifelong mechanical removal of the biofilm. However, outcome is variable. According to recent EFP and AAP reviews, adjunctive antimicrobial therapy may be beneficial. We plan to conduct a double-blind, parallel group, randomized, placebo-controlled multi-center efficacy study that addresses the following objectives:

  1. What is the size of the benefit of an adjunctive empiric antibiotic therapy compared to standard mechanical debridement and oral hygiene instructions in a representative sample of German periodontitis patients?
  2. Does the administration of the antibiotic therapy delay recurrence of periodontitis in the general population and in specific high risk groups (e.g. smokers) under standard supportive therapy?
  3. Is the presence of specific microbial complexes a useful predictor of outcome and recurrence of periodontitis?
  4. Does the administration of the antibiotic therapy affect the "oral health related quality of life"?

The primary hypothesis tested is: the administered empiric adjunctive antibiotic therapy reduces about one half of the proportion of sites with attachment loss compared to subgingival debridement alone over a 27.5-month period in a statistical and clinical significant manner.

To test this hypothesis about 500 patients will be enrolled in the clinical trial. According to the intention-to-treat principle, the primary efficacy analysis will include all randomized subjects. In addition, a per-protocol analysis will be done.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 540 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Adjunctive Antimicrobial Therapy of Periodontitis: Long-Term Effects on Disease Progression and Oral Microbiological Colonization
Study Start Date : October 2008
Actual Primary Completion Date : December 2011
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Antibiotics

Arm Intervention/treatment
Experimental: test
Mechanical debridement plus 500 mg amoxicillin and 400 mg metronidazole three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
Drug: Amoxicillin and Metronidazole
tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
Other Names:
  • Flagyl® 400 Filmtablette
  • Amoxicillin-ratiopharm® 500

Placebo Comparator: control
Mechanical debridement plus two placebo tablets three times daily for 7 days. Supportive periodontal therapy in 3-month intervals.
Drug: Placebo
Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days




Primary Outcome Measures :
  1. Percentage of sites showing attachment loss ≥ 1.3 mm over a 27.5-months period [ Time Frame: 27.5-months period (six measurements) ]

Secondary Outcome Measures :
  1. Subjective perception of treatment outcome, attachment gain, pocket probing depths, bleeding on probing, and full mouth plaque score. Microbial colonization dynamic. [ Time Frame: over a 27.5-months period ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • periodontal screening index (PSI) of IV in at least one sextant;
  • range from 18 to 75 years of age;
  • clinical and radiographic signs of moderate (clinical attachment loss [CAL] of 3 to 4 mm) to severe (CAL 5 mm or more) chronic or aggressive periodontitis;
  • at least 10 natural teeth in situ;
  • pocket probing depths (PPDs) of ≥ 6 mm at a minimum of four teeth;
  • willingness to participate and to be available at all times required for participation;
  • willingness to abstain from using antimicrobial mouth-rinses during the study except for those explicitly prescribed;
  • informed consent signed by the patient;
  • sufficient knowledge of German language.

Exclusion Criteria:

  • if they (or parents or siblings) show confirmed or assumed allergies or hyper-sensitive skin reactions against amoxicillin (or other penicillins or other ingredients of Amoxicillin-ratiopharm® 500mg as listed in the "summary of product characteristics, Version Juli 2005"), metronidazole (or other 5-nitroimidazoles and ingredients of Flagyl® 400mg as listed in the "summary of product characteristics, Version Juli 2007"), systemic diseases or conditions as listed in the above mentioned "summary of product characteristics", or show confirmed lactose intolerance;
  • have Down's syndrome;
  • known AIDS/HIV;
  • regularly take systemic medication affecting the periodontal conditions, e.g. phenytoin, nifedipine, and/or steroid drugs;
  • professional periodontal therapy during 6 months prior to baseline;
  • require antibiotic treatment for dental appointments;
  • are undergoing or require extensive dental or orthodontic treatment;
  • are pregnant or breastfeeding;
  • have rampant caries;
  • any oral or extraoral piercing in or around the oral cavity with ornaments or accessory jewelry;
  • are dental students or dental professionals;
  • have participated in a clinical dental trial in the six months preceding the study;
  • cognitive deficits.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00707369


Locations
Layout table for location information
Germany
Medizinische Fakultät der Humboldt Universität Berlin (Charité)
Berlin, Germany, 13353
Universitätsklinikum Carl Gustav Carus, Zentrum für Zahn-, Mund- und Kieferheilkunde
Dresden, Germany, 01307
Zentrum der Zahn-, Mund- und Kieferheilkunde (Carolinum), Poliklinik für Parodontologie
Frankfurt, Germany, 60590
Justus-Liebig-Universität Gießen, Poliklinik für Parodontologie
Giessen, Germany, 35392
Universitätsklinikum Greifswald, Poliklinik für Zahnerhaltung, Parodontologie und Kinderzahnheilkunde
Greifswald, Germany, 17487
Universitätsklinikum Heidelberg, Poliklinik für Zahnerhaltungskunde, Sektion Parodontologie
Heidelberg, Germany, 69120
University Hospital Muenster, Dept. of Periodontology
Muenster, Germany, 48149
Universität Würzburg, Poliklinik für Parodontologie
Würzburg, Germany, 97070
Sponsors and Collaborators
University Hospital Muenster
Investigators
Layout table for investigator information
Principal Investigator: Benjamin - Ehmke, PhD University Hospital Muenster, Dept. of Periodontology

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Benjamin Ehmke, Prof. Dr. med. dent., University Hospital Muenster
ClinicalTrials.gov Identifier: NCT00707369     History of Changes
Other Study ID Numbers: EH 365/1-1
DFG grant: EH 365/1-1
ISRCTN : 64254080
First Posted: June 30, 2008    Key Record Dates
Last Update Posted: March 3, 2015
Last Verified: March 2015

Keywords provided by Benjamin Ehmke, University Hospital Muenster:
Periodontitis
Mechanical Debridement
Antibiotics
Attachment loss
Randomized controlled trial

Additional relevant MeSH terms:
Layout table for MeSH terms
Periodontitis
Disease Progression
Periodontal Diseases
Mouth Diseases
Stomatognathic Diseases
Disease Attributes
Pathologic Processes
Amoxicillin
Metronidazole
Anti-Bacterial Agents
Anti-Infective Agents
Antiprotozoal Agents
Antiparasitic Agents